logo
  

Roche To Launch Short Duration Infusion Gazyvaro For Patients In The EU - Quick Facts

Roche (RHHBY) reported EMA approval of a shorter 90-minute Gazyvaro infusion time, administered in combination with chemotherapy in patients with previously treated or untreated advanced follicular lymphoma. The regular rate of infusion can take approximately three to four hours, the company noted.

Levi Garraway, Chief Medical Officer, said: "Reducing the amount of time patients need to be in hospital has the potential to improve their treatment experience whilst also increasing efficiency for institutions and healthcare systems."

Following the approval, Gazyvaro's label update is being implemented immediately. Also, Roche is planning to launch short duration infusion Gazyvaro for patients in the EU with previously treated and untreated advanced follicular lymphoma as soon as possible.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT